SEARCH

Current Edition

DNA

DNA vaccine spurs antibodies against a common Parkinson’s target in mice

The neuronal protein alpha-synuclein has long been a target for Parkinson’s disease research, but it has delivered mixed results across multiple different therapeutics. Now, a …

18 January 2022 Regional News DNA mice

Continue Reading →

clinical

Fortuna Fix Announces Series B Financing, Adding Amgen Ventures and Macnguyen Family Office as Shareholders

Fortuna Fix, a private, clinical-stage Regenerative Medicine company is aiming to be the first to bring to the clinic a patient’s own neural stem cells …

8 November 2017 news clinical neurotrauma

Continue Reading →

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

SEARCH

MENU

Current Edition

DNA vaccine spurs antibodies against a common Parkinson’s target in mice

Fortuna Fix Announces Series B Financing, Adding Amgen Ventures and Macnguyen Family Office as Shareholders

Journal for Clinical Studies